NervGen Pharma Corp. NGEN
1.45 USD +0.09 (+7.04%)
Nov 12, 2026, 3:23 PM EST
1.45 Day range 1.45
1.28 52-week range 6.30
- YTD
- -74.20%
- 1 year
- -46.28%
- Market cap
- 155.37M
- EPS (ttm)
- -0.57
- YTD return
- -74.20%
- 1-year return
- -46.28%
- Volume
- 2.12M
- Avg volume
- 510.01K
- Open
- 1.45
- Previous close
- 1.35
- Day's range
- 1.45 – 1.45
- 52-week range
- 1.28 – 6.30
5D +0.14 (+10.69%)
Financials — quick view
NGEN Revenue — quarterly 0
NGEN Net income — quarterly 10.80M
NGEN EPS — quarterly 0.12
News
NervGen Says FDA Grants NVG-291 Breakthrough Therapy Designation For Treatment Of Chronic Traumatic Cervical Motor-Incomplete SCI 
NervGen Pharma (NASDAQ:NGEN) Stock Has Consensus Price Target of $14.00 According to Brokerages 
NervGen Doses First Participant In Phase 3 RESTORE Study Of NVG-291 For Chronic Cervical SCI; Enrollment Completion Expected In H2 2027, Topline Data In H1 2028 
NervGen Announces It Will Restate Its Audited Annual Financial Statements For The Year Ended December 31, 2025, And Its Unaudited Interim Financial Statements For The Quarter Ended June 30, 2026 
Micron To Rally Around 87%? Here Are 10 Top Analyst Forecasts For Tuesday 
HC Wainwright & Co. Maintains Buy on NervGen Pharma, Lowers Price Target to $15 - Leerink Partners Initiates Coverage On NervGen Pharma with Outperform Rating, Announces Price Target of $10
12 Health Care Stocks Moving In Wednesday's After-Market Session - NervGen Pharma Increases Mixed Shelf Offering From $150M To $250M
Why Is NervGen Pharma Stock Gaining Tuesday?
Your note
Sign in to keep a note on NGEN — it syncs with the Stock Master app.